Press Releases Sep 15, 2023 NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH Aug 14, 2023 NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT Aug 09, 2023 NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update View All Events Dec 22, 2022 at 10:00 AM EST Virtual Stockholder’s Meeting Jun 9, 2022 at 10:00 AM EDT 2022 Annual Meeting Aug 18, 2021 at 10:00 AM EDT Virtual Stockholder’s Meeting View All Annual Report 2021 Annual Report View All Financial Metrics Price Change Volume Today's Open Previous Close Sep 25, 2023 11:59 AM EDT Stock Chart Today 3 mo. 6 mo. 1 yr. Data Provided by Refinitiv. Minimum 15 minutes delayed. View All Financial Information Corporate Governance Stock Information Investor FAQs Information Request
Sep 15, 2023 NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
Aug 14, 2023 NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT
Aug 09, 2023 NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
